...
首页> 外文期刊>AJR: American Journal of Roentgenology : Including Diagnostic Radiology, Radiation Oncology, Nuclear Medicine, Ultrasonography and Related Basic Sciences >Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
【24h】

Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.

机译:放射栓塞作为葡萄膜黑色素瘤肝转移的挽救疗法:单机构经验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: The purpose of this study was to assess the safety and efficacy of radioembolization in the management of hepatic metastasis of uveal melanoma after failure of immunoembolization or chemoembolization. MATERIALS AND METHODS: From January 2007 through April 2009, 32 patients underwent radioembolization therapy for hepatic metastasis of uveal melanoma. Pretreatment tumor burdens were divided into three categories: less than 25% (n = 25), 25-50% (n = 5), and greater than 50% (n = 2). Toxicity, extrahepatic disease, and hepatic tumor response were assessed 1 month and then every 3 months after treatment. Best radiographic response of hepatic metastasis was determined with the Response Evaluation Criteria in Solid Tumors criteria. Overall survival and progression-free survival of hepatic metastasis were estimated by Kaplan-Meier analysis. Differences in survival between subgroups were evaluated by log-rank test in univariate analysis. RESULTS: The clinical follow-up period ranged from 1.0 to 29.0 months (median, 10.0 months). The median overall survival was 10.0 months, and the progression-free survival of hepatic metastasis, 4.7 months. Twenty-two patients died 1.0-29.0 months (median, 5.8 months) after treatment owing to progression of liver disease (n = 13), extrahepatic disease (n = 4), or both (n = 5). Patients who had a pretreatment tumor burden less than 25% had longer median overall survival (10.5 vs 3.9 months, p = 0.0003) and progression-free survival (6.4 vs 3.0 months, p = 0.03) than patients who had a pretreatment tumor burden of 25% or greater. Patients who had a complete response (n = 1), partial response (n = 1), or stable disease (n = 18) had longer median overall survival (14.7 vs 4.9 months, p = 0.0006) and progression-free survival of hepatic metastasis (7.9 vs 3.1 months, p < 0.0001) than patients with tumor progression (n = 12). Self-limiting grade 1-2 systemic toxicity included tiredness (n = 9), indigestion (n = 2), and abdominal discomfort (n = 5). Grade 3-4 hepatic toxicity was attributed to tumor progression. CONCLUSION: Radioembolization is safe and effective salvage therapy for limited metastasis of uveal melanoma.
机译:目的:本研究的目的是评估在免疫栓塞或化学栓塞失败后,葡萄膜栓塞治疗葡萄膜黑色素瘤肝转移的安全性和有效性。材料与方法:自2007年1月至2009年4月,32例患者因葡萄膜黑色素瘤的肝转移接受了放射栓塞治疗。治疗前的肿瘤负担分为三类:小于25%(n = 25),25-50%(n = 5)和大于50%(n = 2)。在治疗后1个月,然后每3个月评估毒性,肝外疾病和肝肿瘤反应。肝转移的最佳放射照相反应是根据《实体瘤反应评估标准》确定的。通过Kaplan-Meier分析评估了肝转移的总体生存期和无进展生存期。通过单因素分析中的对数秩检验评估亚组之间的生存差异。结果:临床随访期为1.0至29.0个月(中位数为10.0个月)。中位总生存期为10.0个月,肝转移无进展生存期为4.7个月。 22名患者因肝病(n = 13),肝外疾病(n = 4)或两者(n = 5)的进展在治疗后1.0-29.0个月(中位数为5.8个月)死亡。术前肿瘤负荷低于25%的患者比术前肿瘤负荷为25%的患者具有更高的中位总生存期(10.5 vs 3.9个月,p = 0.0003)和无进展生存期(6.4 vs 3.0个月,p = 0.03)。 25%或更高。完全缓解(n = 1),部分缓解(n = 1)或疾病稳定(n = 18)的患者中位总生存期较长(14.7 vs 4.9个月,p = 0.0006),肝无进展生存期转移(7.9 vs 3.1个月,p <0.0001)比肿瘤进展患者(n = 12)。自我限制的1-2级全身毒性包括疲倦(n = 9),消化不良(n = 2)和腹部不适(n = 5)。 3-4级肝毒性归因于肿瘤进展。结论:放射栓塞是葡萄膜黑色素瘤有限转移的安全有效的挽救疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号